Fasting glucose, HbA1c, and fasting insulin
Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry)
Tirzepatide: Also a dual agonist that targets both GLP-1 and GIP receptors, which helps regulate blood sugar more effectively and may lead to greater weight loss in comparison to Semaglutide
Thats why screening for these conditions is a critical part of confirming a diagnosis and planning effective care
Once approval is secured, you gain access to 24/7 care support
[DOI] [PubMed] [Google Scholar] 89.Omotosho I.O., Akinade A.O., Lagunju I.A., Yakubu M.A